

Group 1 Patients

Neutralising Monoclonal Antibodies for Patients Hospitalised due to COVID-19

Guidance for use in GGC

Neutralising monoclonal antibodies (nMAB) bind to specific sites on the spike protein of the SARS-CoV-2 virus particle, blocking its entry into cells and therefore inhibiting its replication.

There is currently NO nMAB suitable for standard care treatment in Group 1 patients due to the predominance of the omicron variant, >90% of GGC cases

The following nMABs have conditional marketing authorisation for use in the treatment of COVID-19 in the UK.

- Sotrovimab (Xevudy®) is an nMAB that both blocks viral entry into healthy cells and clears cells infected with SARS-CoV-2.
- Casirivimab and imdevimab (Ronapreve®) is not effective against omicron variant so not currently used in GGC.

Sotrovimab is not currently commissioned for treatment of Group 1 patients. Group 1 patients (including pregnant patients) may be considered for treatment with sotrovimab within the RECOVERY Clinical Trial only. Please contact the following Principle Investigators and the Clinical Research Facility to discuss further:

QEUH	Prof Malcolm Sim Prof Kevin Blyth
GRI	Dr Kathryn Puxty
RAH	Dr Alasdair Corfield
IRH	Dr Azharuddin Mohammed
RHC (patients aged 12-16)	Paediatric ID Consultant On-Call
Clinical Research Facility Teams	Glasgow.CRF@ggc.scot.nhs.uk